<DOC>
	<DOC>NCT01365104</DOC>
	<brief_summary>The purpose of this study is determine if the iron chelator, desferrioxamine can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.</brief_summary>
	<brief_title>Modulation of Cerebral Blood Flow Using Iron Chelators</brief_title>
	<detailed_description />
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>healthy adults between the ages of 1880 years. subjects taking vasoactive medications, hypertension, pregnant women, smokers, COPD, asthma, diabetes mellitus, intracranial or carotid stenosis, hepatic disease, renal disease, bone marrow suppression, cardiac disease, heart failure, iron deficiency, history of cancer, history of head trauma, subarachnoid hemorrhage, central nervous system vasculitis, multiple sclerosis, migraines, seizures, sickle cell disease or trait, cardiac arrhythmia, unable to give informed consent, or poor transcranial Doppler insonation windows.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>brain blood flow</keyword>
	<keyword>stroke</keyword>
	<keyword>cerebrovascular</keyword>
	<keyword>aging</keyword>
	<keyword>cerebrovascular hemodynamics</keyword>
</DOC>